Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (DE:8AK)
BERLIN:8AK
Alkermes (8AK) Stock Price & Analysis
0 Followers
8AK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€20.80 - €29.80
Previous Close€25.6
Volume0.00
Average Volume (3M)45.00
Market Cap
€4.22B
Enterprise Value€3.88B
Total Cash (Recent Filing)$745.05M
Total Debt (Recent Filing)$370.11M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Oct 23, 2024EPS Estimate
€0.66Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding164,136,728
10 Day Avg. Volume28
30 Day Avg. Volume45
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)5.13
Price to Cash Flow (P/CF)28.20
P/FCF Ratio45.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.75
Enterprise Value/Ebitda6.42
Forecast
1Y Price Target
€33.07Price Target Upside29.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Alkermes News
PremiumPre-Earnings
Is ALKS a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsALKS-2680 advancing in narcolepsy Phase 2 trials, representing significant potential opportunity.
EarningsStrong 2Q24 performance with core products beating consensus expectations.
Share RepurchaseAlkermes repurchased ~$3.5M shares for ~$85M, with ~$315M remaining under the program, which should further help improve the EPS growth profile.
Bears Say
EarningsNon-GAAP EPS of $0.43 missed Consensus largely due to higher-than-expected spending.
Financial Performance1Q24 results were soft, due primarily to an unusually high level of wholesaler destocking of Vivitrol, Aristada, and Lybalvi.
Market CompetitionHarmony Biosciences has entered the space as well, resulting in an even more crowded market.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.40% Other Institutional Investors
99.60% Public Companies and
Individual Investors
8AK FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was €20.80 and its highest was €29.80 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Oct 23, 2024 which is in 88 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Jul 24, 2024. The company reported €0.645 earnings per share for the quarter, missing the consensus estimate of €0.648 by -€0.004.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of €1.51 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is €0.66.
How many shares outstanding does Alkermes have?
Currently, no data Available
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of €0.645 in its last earnings report, missing expectations of €0.648. Following the earnings report the stock price went up 10.714%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is PRIMECAP Management Co. It holds Alkermes’s shares valued at 94M.
---
Alkermes Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€33.07 (29.19% Upside)
€33.07 (29.19% Upside)
Blogger Sentiment
Bullish
DE:8AK Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.19%
12-Months-Change
Fundamentals
Return on Equity
26.67%
Trailing 12-Months
Asset Growth
0.90%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
8AK Company Deck
---
8AK Earnings Call
Q2 2024
0:00 / 0:00
---
8AK Revenue Breakdown
55.31% Product sales, net
44.69% Manufacturing and royalty revenues
<0.01% Research and development revenue
0.00% License revenue
---
8AK Stock 12 Month Forecast
Average Price Target
€33.07
▲(29.19% Upside)
Technical Analysis
Alkermes
―
Aptose Biosciences
―
Catalyst Pharma
―
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Best Analysts Covering 8AK
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+6.42%
assigned a buy rating 2 months ago
Copying Akash Tewari's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +6.42% per trade.
---